As we bid farewell to 2019, we proudly reflect on a year replete with milestones and forward strides for CURE. 2019 marked a significant level of progress that stemmed from our strong patent positioning and pipeline advancement. In 2019, we attracted a deep bench of scientific and industry talent to our staff and board of directors who will support our long-term growth strategies. We completed a strategic acquisition, entered into key partnerships, expanded our product line and IP portfolio, and advanced our product pipeline.
We are delighted to share with you some of the exciting moments and achievements we celebrated this past year.
CURE’s 2019 Highlights
Chemistry Holdings Acquisition
We successfully acquired Chemistry Holdings Inc., a formulation technology company in a deal that added novel intellectual property and scientific expertise to CURE’s capabilities, helping us deliver on our promise to transform patient’s lives with breakthrough drug delivery technologies.
Government Green Lights
We broadened our previously acquired U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD) using our CUREfilm® technology. In addition, we successfully completed our pre-IND (Investigational New Drug) review with the U.S. Food and Drug Administration (FDA) for our clinical development plans for CUREfilm® Blue, a soluble thin film for oral administration of sildenafil citrate to treat erectile dysfunction.
We began a collaboration with Canopy Growth Corporation, launching the development of a new low-dose cannabidiol (CBD) oral thin film using CURE’s patented CUREfilm® technology. This collaboration builds on our 2018 licensing agreement with Canopy Growth, a leading international cannabis company.
In addition, we entered into a five-year agreement with Meroven LLC to manufacture and supply Spee-D®, a weekly dose oral thin film Vitamin D3, using our patented CUREfilm® technology. Meroven will exclusively market and distribute Spee-D® in the United States.
We also signed a deal with Oklahoma-based hemp grower Fytiko Farms to secures our hemp CBD supply chain and guarantees CURE direct access to high-quality organic hemp extracts for use in CURE products, through strain improvement, cannabinoid extraction process development, biomarker identification and quality control testing.
Product Line Expansion
We announced CUREform™, our expanded oral drug delivery product line that includes our flagship product, CUREfilm®, microCURE™ emulsions, and CUREpods™ chewables. We launched CUREfilm® Hemp as well as Hemp shots delivered using our microCURE™ technology. The CUREfilm® Sleep products (Sleep Stripzzz and ID Life – Sleep Aid) are also available for purchase.
Intellectual Property Expansion
In 2019, we secured five issued U.S. patents, one China allowed patent, and filed 13 new applications with the United States Patent and Trademark Office. CURE now has a total of 13 issued patents worldwide.
Our team grew this year, including key hires: Michael Redard as our Chief Financial Officer, Bhaumik Patel as our Director of New Technologies, and Donna Hudson as our Director, Quality & Compliance Systems. We expanded our board of directors with the addition of Ruben Jose King-Shaw Jr., Dr. Lauren Chung, Anya Goldin, John K. Bell, and Joshua Held. Additionally, our former VP of Strategy, Dr. Vered Gigi stepped into a new role as our Chief Scientific Officer.
In 2019, we were honored to receive the “Innovative Business of the Year” award from the Oxnard Chamber of Commerce. We are also proud to be included in the Green Entrepreneur “Top 100 Cannabis Companies” list and to be named the #1 Fastest Growing Company in the Tri-County area by the Pacific Coast Business Times.
CURE’s Investment in Coeptis
We announced the purchase of a $200,000 convertible promissory note from Coeptis Pharmaceuticals, Inc. The note represented an initial step toward CURE’s potential acquisition of the company and the exclusive rights to Coeptis’ approved drug Consensi®, the first fixed-dose combination drug for the treatment of comorbid osteoarthritis and hypertension whose potential to significantly reduce the pill burden for patients aligned with CURE’s core mission to improve drug delivery and medication adherence.
Despite the strategic merits of the proposed transaction, the parties were unable to arrive at mutually agreeable terms to complete the acquisition and negotiations related to the acquisition have terminated.
We plan to continue to pursue strategic acquisition and investment opportunities to expand CURE’s drug portfolio, particularly in areas where our expertise, experience, and resources can create value for CURE shareholders and uphold our core mission.
As we move forward into 2020, we believe we are well-positioned to execute on our long-term strategic plan.
CURE in the Community
We continued our committment to giving back to our community through our relationship with Ventura County Food Share. Our staff, including members of our executive team, volunteered quarterly at the food bank, planting and harvesting produce, weeding the vegetable garden and packing canned food for distribution to families in need.
2019 also saw the launch of our global healthcare awareness initiative with United Smart Cities for the purpose of educating, informing and providing the next generation healthcare solutions worldwide.
Interested in Investing in CURE?
Our website has a section dedicated to investor education and information about CURE. Visit our website to review our SEC filings, recent news, and company information. You can also download our latest investor presentation and message us via the website contact form.
On February 28, 2017, and ending on August 28, 2020, Liviakis Financial Communications, Inc. (LFC) was retained by CURE Pharmaceutical Holding Corp. (CURR) in various consulting capacities including strategic management planning, investor relations and other business development responsibilities. LFC was compensated 1,000,000 restricted common stock under rule 144. Officers and employees of LFC will buy or sell shares in CURE Pharmaceutical Holding Corp. prior, during or after this release. LFC advises CURE Pharmaceutical Holding Corp. but does not provide investment advice. LFC is not a registered investment advisor or broker-dealer. All material provided regarding CURE Pharmaceuticals Holding Corp. including, but not limited to its history, corporate status, and other developments was prepared using information approved and signed off by CURE Pharmaceutical Holding Corp. management as approved for public dissemination. Although the information contained herein is believed to be reliable, LFC makes no warranties as to the accuracy of the description of any of the content herein and accepts no liability for how readers may choose to utilize it.